Biomerieux, Inc.

Centre National De La Recherche Scientifique

Institut Curie

Dominique Rolland

Jean-Philippe Charrier

Corinne Beaulieu

Genevieve Choquet-Kastylevsky

Sandrine Busseret

Yasemin Ataman-Onal

Geneviève Choquet-Kastylevsky

Yasemin Ataman-Önal

Yasemin Ataman-Oenal

Monique Arpin

Odile Mejan-Letourneur

Sylvie Pons

Yasmin Ataman-Onal

Odile Mejan-letourneur

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer

A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer

The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.

A method for the in vitro diagnosis of colorectal cancer by determining the presence of Aminoacylase 1 tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3.

Protein disulfide isomerase assay method for the in vitro diagnosis of colorectal cancer

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4+SEQ ID No. 5, SEQ ID No. 6+SEQ ID No. 7 and SEQ ID No. 8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Growing community of inventors

Saint Genis les Ollieres, France

Dominique Rolland